Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The antibody-drug conjugate (ADC), which was originally developed under a partnership between Seagen and Genmab, was granted accelerated approval in September 2021 based on a 24% objective response rate seen in the Phase II innovaTV 204 trial
excess or altered GIP signalling may contribute to obesity
The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan
Researchers say their findings mean that GLP-1s should be considered as a potential treatment for respiratory diseases
US$ 24.43
US$ 20.78
US$ 26.69
US$ 21.60
US$ 22.46
US$ 25.90
